Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations—NOTCH1, SF3B1, MYD88, BIRC3
Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with extremely variable clinical course. The clinical heterogeneity of CLL reflects differences in the biology of the disease, including chromosomal alterations, specific immunophenotypic patterns and serum markers. The application of next-...
Main Authors: | Maciej Putowski, Krzysztof Giannopoulos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/16/3735 |
Similar Items
-
BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
by: Raffaele Frazzi
Published: (2021-01-01) -
Filtered Kombucha Tea Rings the Bell for TLR2, TLR4, MYD88, and Dectin-1 in Mice Model of Colitis
by: Elaheh Mahmoudi*, et al.
Published: (2020-07-01) -
Crucial role for T cell-intrinsic IL-18R-MyD88 signaling in cognate immune response to intracellular parasite infection
by: Ana-Carolina Oliveira, et al.
Published: (2017-09-01) -
MyD 88 Polymorphisms in Children Diagnosed with Sepsis
by: Sinem Sarı Gökay, et al.
Published: (2016-12-01) -
Antimicrobial Peptide Epinecidin-1 Modulates MyD88 Protein Levels via the Proteasome Degradation Pathway
by: Bor-Chyuan Su, et al.
Published: (2017-11-01)